KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

B-ALL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

First Affiliated Hospital of Zhejiang University, Hangzhou, China
Contact: Study coordinator (He Huang, MD/PhD) · +（86）0571-87236703

Study leads

He Huang, MD
Principal Investigator
First Affiliated Hospital of Zhejiang University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

B-ALL · Leukemia

Abroad (travel likely)RecruitingPHASE1

Johannesburg, South Africa · Pretoria, South Africa

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Jacksonville, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

B-NHL · B-ALL

Abroad (travel likely)Recruiting

Zhenzhou, China